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Abstract The role of busulfan (Bu) metabolites in the ad-
verse events seen during hematopoietic stem cell transplanta-
tion and in drug interactions is not explored. Lack of
availability of established analytical methods limits our un-
derstanding in this area. The present work describes a novel
gas chromatography–tandemmass spectrometric assay for the
analysis of sulfolane (Su) in plasma of patients receiving
high-dose Bu. Su and Bu were extracted from a single
100 μL plasma sample by liquid–liquid extraction. Bu was
separately derivatized with 2,3,5,6-tetrafluorothiophenol
fluorinated agent. Mass spectrometric detection of the
analytes was performed in the selected reaction moni-
toring mode on a triple quadrupole instrument after
electronic impact ionization. Bu and Su were analyzed
with separate chromatographic programs, lasting 5 min
each. The assay for Su was found to be linear in the
concentration range of 20–400 ng/mL. The method has sat-
isfactory sensitivity (lower limit of quantification, 20 ng/
mL) and precision (relative standard deviation less than
15 %) for all the concentrations tested with a good trueness
(100±5 %). This method was applied to measure Su from
pediatric patients with samples collected 4 h after dose 1
(n046), before dose 7 (n056), and after dose 9 (n054)
infusions of Bu. Su (mean±SD) was detectable in plasma
of patients 4 h after dose 1, and higher levels were ob-
served after dose 9 (249.9±123.4 ng/mL). This method
may be used in clinical studies investigating the role of
Su on adverse events and drug interactions associated with
Bu therapy.
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Introduction
Busulfan (Bu) is one of the most commonly used alkylat-
ing agents in the myeloablative conditioning regimen
before hematopoietic stem cell transplantation [1, 2].
Hepatic veno-occlusive disease, pulmonary interstitial fi-
brosis, mucositis, and convulsions are the common ad-
verse events seen with Bu therapy. Studies have shown
association of these adverse events with high plasma
levels of Bu, especially in children [3, 4]. However,
occurrence of these events cannot be completely explained
by the Bu plasma levels [5]. Indeed, the mechanisms of
the adverse events are not clearly understood, and the role
of Bu and its reactive metabolites on elucidating these
events or their interaction with co-administered drugs is
not clearly known.
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Bu is metabolized by liver cytosolic glutathione-S-transfer-
ase enzymes (GST isoforms GSTA1-1, GSTM1-1, and
GSTP1-1) to form a positively charged conjugate known as a
sulfonium ion conjugate [γ-glutamyl-β-(S-tetrahydrothiophe-
nium)-alanyl-glycine], which dissociates non-enzymatically at
alkaline pH and 37 °C or by enzymatic reaction catalyzed by
cystathionine-γ-lyase to tetrahydrothiophene (THT), pyruvate,
and ammonia [6, 7]. THT is a lipophilic, volatile heterocyclic
small molecule that gets oxidized to THT1,1-dioxide or sulfo-
lane (Su) via the formation of THT,1-oxide [8, 9]. THT, 1-
oxide, Su, and its oxidation product 3-hydroxy Su have been
identified as the urinary metabolites of Bu in humans [10]. It is
presumed that several cytochrome P 450 enzymes (CYP iso-
forms) might play a role in the oxidation of THT to Su and in
the formation of 3-hydroxy Su. It is also presumed that these
metabolites might play a role in altering the metabolism of
cyclophosphamide administered after Bu. However, there are
no data available on CYP isoforms catalyzing these oxidation
reactions or on the distribution and fate of the metabolites, due
to the lack of established analytical methods.
Two analytical methods for THT measurement have been
described in the literature, and applied to in vitro and in vivo
experiments [11, 12]. Nevertheless, the use of these methods
for plasma level measurements of THT is tedious, and the
detection of THT in samples collected during clinical stud-
ies is problematic due to its volatile nature. THT 1,1-dioxide
or Su is a small molecule that is relatively stable compared
to THT and is an immediate metabolite formed after oxida-
tion of THT1-oxide. Su undergoes oxidation to 3-hydroxy
Su, which is excreted in urine due to its hydrophilic nature
[10]. Su is thus an important relatively stable intermediate
metabolite, and its levels in plasma may be indicative of the
metabolic fate of Bu. Even though a method for Su deter-
mination from ground water was described for environmen-
tal investigations [13], to the best of our knowledge, no
method has been described in the literature for Su quantifi-
cation in the plasma of patients receiving intravenous Bu.
In this article, we describe a novel gas chromatography–
tandemmass spectrometric (GC–MS/MS)method for the mea-
surement of Su in human plasma micro samples. This method
can be easily implemented alongwith Bumeasurements during
routine monitoring without requiring additional sample volume
using the same analytical platform.We believe that this strategy
represents an efficient tool for the evaluation of metabolite
distribution in patients receiving higher doses of Bu.
Material and methods
Samples collection
Clinical samples were obtained from patients who underwent
hematopoietic stem cell transplantation in the Department of
Pediatric Hematology and Oncology of the University Child-
ren’s Hospital, Geneva, Switzerland (n03) and in the Depart-
ment of Pediatrics of CHU Sainte Justine, Montreal, Canada
(n056). The protocol was approved by the local hospital ethics
committee, and each patient/parent signed a consent form.
These samples were collected for routine therapeutic
drug monitoring of Bu, as explained elsewhere [14], under
an ongoing European Group for Bone Marrow Transplant
Bu polymorphism study. The study was conducted accord-
ing to the revised Declarations of Helsinki, the standards of
Good Clinical Practice, and the Swiss regulatory require-
ments. The blank plasma used for calibration and validation
was composed of Bu and Su-free pooled plasma provided
by the University Hospital of Geneva.
Chemicals and reagents
Reference Su (>99.5 % pure), Bu, and 2,3,5,6-Tetrafluorothio-
phenol (TFTP) were purchased from Sigma-Aldrich (Stein-
heim, Germany). Su-d8 (99 % atoms deuterated Su) was
obtained from ARMAR Chemicals (Döttingen, Switzerland),
and Bu-d8 was provided by Toronto Research Chemicals Inc.
(Toronto, Canada). These reference materials were stored at
room temperature. Ethyl acetate and acetonitrile (HPLC grade)
were obtained from Merck (Darmstadt, Germany). Isopropa-
nol (>99.5 % pure) solvent, dried over molecular sieves, was
obtained from Fluka (Buchs, Switzerland).
Stock solutions of Su and Su-d8 were prepared by weigh-
ing 10 mg (corresponding to 8 μL) of pure substances into
10 mL of Milli-Q water. As both Su and Su-d8 are solids at
room temperature (melting point, 27.5 °C), small fragments of
reference materials were thawed by heating at 35 °C. Working
standard solutions [0.1 and 1 μg/mL for Su, 10 μg/mL for Su-
d8 as the internal standard (IS1)] were prepared by dilution in
Milli-Q water. Stock and working standard solutions were
freshly prepared when needed. A stock solution of Bu was
prepared by weighing 10 mg of pure substance in 10 mL of
acetonitrile. A stock solution of Bu-d8 was prepared by add-
ing 1 mL of acetonitrile into the original flask containing
2.5 mg of pure substance. Working standard solutions [1 and
10 μg/mL for Bu, 2.5 μg/mL for Bu-d8 (IS2)] were then
prepared in Milli-Q water. Stock and working standard solu-
tions were stored at −20 °C.
Preparation of calibrators
Working standard solutions were used to spike drug-free plas-
ma to reach the concentrations of interest. Calibration samples
were prepared by adding the corresponding volume of ade-
quate standard solution in 100 μL of blank plasma. Final
concentrations of 500 ng/mL for Su-d8 (IS1) and 250 ng/mL
for Bu-d8 (IS2) were achieved by adding 5 and 10 μL of the
corresponding working standard solutions, respectively.
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Sample pretreatment
After spiking with ISs and adding 50 μL of 1 M NaOH,
100 μL of plasma was extracted with 500 μL of ethyl acetate
by horizontal shaking (20 moves/s) for 5 min. After centrifu-
gation (14,800 rpm, 1 min), the organic layer was removed. A
100-μL aliquot was separated for Bu quantitation. A 50-μL
aliquot of isopropanol was added to the remaining 400 μL,
and the ethyl acetate was evaporated under a gentle flow of
nitrogen at room temperature for approximately 10 min. A 1-
μL aliquot of the remaining 50-μL isopropanolic residue was
injected into the GC–MS/MS system.
The 100-μL remaining aliquot for Bu quantitation was
treated as described by Quernin et al., with the following
alterations [15]. Briefly, 100 μL of Milli-Q water, 25 μL of
1 M NaOH, and 10 μL of pure TFTP were added to the 100-
μL organic phase. After mixing, the derivatization was
achieved by heating at 60 °C for 30 min. After cooling,
200 μL of ethyl acetate was added to the mixture for back
extraction by strong horizontal shaking (20 moves/s). After
centrifugation, the organic layer was evaporated to dryness
under a gentle stream of nitrogen at room temperature. The
residue was reconstituted in 50 μL of ethyl acetate, and
1 μL was injected into the GC–MS/MS system. The
overall extraction procedure is summarized in the Electronic
supplementary material (ESM) Fig. 1.
GC–MS/MS analysis
Analyses were performed on a Varian CP 3800 gas chro-
matograph (Walnut Creek, USA), equipped with a Varian
CP-8400 autosampler and a Varian 300-MS triple quadru-
pole mass spectrometer. Data acquisition and analysis
were performed through the Varian MS workstation soft-
ware (version 6.9.3). Chromatographic separation was
made on a Zebron fused-silica capillary column (ZB-5
MS, 15 m×0.25 mm i.d., film thickness 0.25 μm, with
a 10-m inert guard column) from Phenomenex (Torrance,
USA). High-purity helium 50 (99.999 %) was used as the
carrier gas with a constant flow of 1 mL/min. The injector
temperature was set to 250 °C, and the injection was
made in splitless mode, with the injection purge valve
remaining closed for 1 min.
For Su quantitation, the initial oven temperature was set to
60 °C and held for 0.1 min. It was then increased to 82 °C at
70 °C/min and held for 1min, increased to 105 °C at 70 °C/min
and held for 0.5 min, increased to 280 °C at 70 °C/min, and
finally maintained for 0.26 min. For Bu quantitation, the initial
oven temperature was set to 60 °C and held for 0.5 min. It
was increased to 200 °C at 70 °C/min and then to 280 °C
at 50 °C/min. The final temperature was maintained for
0.90 min. Both GC runs lasted 5 min only. The transfer
line, manifold, and ion source were heated at 275, 40, and
200 °C, respectively. Ionization was achieved in electronic
impact mode (EI) at 70 eV. The MS/MS experiments were
based on collisionally induced dissociation, which occurred
in the collision cell with an argon pressure of 1.5 mTorr.
Two selected reaction monitoring transitions were consid-
ered for each analyte (Table 1). They were chosen accord-
ing to their selectivity and sensitivity.
Validation procedure
The method was validated according to the European Med-
icines Agency guidelines [16]. The validation was carried
out over three nonconsecutive days (p03). A statistical
treatment of the results, based on variance analysis, allowed
a determination of the precision and trueness of the method
for the selected concentration levels.
A validation day consisted of independently preparing
calibrators and quality control samples (QC) with both
analytes spiked in the same sample. Calibrators were pre-
pared in duplicate (n02) at five concentrations levels, i.e.,
20, 50, 100, 200, and 500 ng/mL for Su and 50, 200, 500,
1,000, and 2,000 ng/mL for Bu. These samples allowed the
determination of the response functions of both analytes,
calculated with the analyte to internal standard ratios. The
calibration range was chosen according to the concentra-
tions observed in a patient’s samples during the pre-
validation step. The QC samples were prepared indepen-
dently in quadruplicate (n04) at four concentration levels,
i.e., 20, 40, 100, and 400 ng/mL for Su and 100, 200, 500,
and 2,000 ng/mL for Bu.
The spiked samples were then treated as described earlier.
The validation procedure permitted the determination of
trueness, precision, linearity, and the limits of quantification.
The lower limit of quantification (LLOQ) was determined as
the lowest QC concentration with trueness and precision
under ±20 %. The overall extraction recovery of Su was
evaluated by comparison of the extracted samples with a
non-extracted isopropanolic solution.
Table 1 MS/MS method parameters for busulfan and sulfolane
Compound Molecular
mass (g/mol)
Retention
time (min)
Q1→Q3
(m/z)
Collision
energy (eV)
di-TFTP
butane d8
426 3.91 426→245 10
di-TFTP butane 418 3.92 418→237 10
237→195 10
Sulfolane d8 128 2.88 128→62 10
Sulfolane 120 2.90 120→55 10
120→41 15
Quantitative transitions are underlined; the others were used for
identification
d8 deuterated; TFTP 2,3,5,6-tetraflurothiophenol
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Recovery and stability tests
The stability of Bu in frozen plasma has already been
investigated, and no further experiments were performed
in this study [17]. The extraction procedure was also taken
from the literature and was not re-evaluated [15]. The
short-term stability of Su in plasma was evaluated at
100 and 400 ng/mL levels. These samples were analyzed
in triplicate on the day 0, and aliquots were stored at −20 °C.
They were then analyzed after 7, 14, 21 (n01), and 90 days
(n03). The extraction recovery of Su was evaluated by
comparing the Su peak areas of the extracted spiked plasma
(n06) with a corresponding isopropanolic solution injected
six times.
Results and discussion
Two difficulties had to be overcome in the development of a
quantitative analytical method for Su along with Bu in pedi-
atric plasma samples. First, Bu is not volatile enough for gas
chromatography. Several derivatization protocols have been
proposed to avoid this incompatibility [15, 18–20], and liquid
chromatography methods coupled to mass spectrometry are
common [21, 22]. However, the objective of this study was to
quantify the Su in the patients’ single plasma sample along
with Bu, which seemed to be more feasible by GC due to the
nature of Su. The Bu extraction and derivatization procedure
described by Quernin et al. was chosen and adapted for this
purpose [15].
The physical properties of Su were also problematic for
sample preparation. Evaporation to dryness of the working
standard solutions or extracts followed in conventional pro-
cedures could not be performed. Indeed, incoherent peak
areas or even complete disappearance of Su was observed
during the pre-validation step after evaporation of the meth-
anolic standard solutions and extracts to dryness using ni-
trogen or evaporating under vacuum. This was probably due
to the partial or complete evaporation or sublimation of Su
occurring after solvent elimination at room temperature.
This problem was solved by spiking the plasma sample
directly with aqueous solutions of Su and Su-d8, and
adding isopropanol in the ethyl acetate extract before
evaporation. Isopropanol is fully miscible in ethyl acetate
in the used proportions and has a lower volatility. This
property allows for better control of the evaporation of the
extracts. Moreover, isopropanol was found to be a suitable
solvent for GC. The extraction recovery was estimated to be
93 % (n06, 6 % RSD).
The second difficulty was the small amount sample ma-
terial because Bu derivatization step seemed to be incompat-
ible with Su analysis. Indeed, no Su peak could be detected
after Bu derivatization of the spiked plasma. Thus, two
separated sample preparations had to be investigated, pref-
erably from a single plasma sample of reasonable volume.
Nevertheless, concentrations found in real clinical samples
during the pre-validation step were sufficiently high to suit
the instrument sensitivity without extensive pre-concentration.
Therefore, a volume of 100 μL of plasma, split into two
fractions after the addition of organic solvent, was found to
be a good compromise between the sensitivity needs and the
scarcity of available sample.
GC–MS/MS analysis of busulfan and sulfolane
Two MS/MS transitions were investigated for Su, although
its nominal mass was small (120 u). As illustrated in Fig. 1a,
the EI of Su showed predominant fragment ions of mass to
charge ratio (m/z) of 41, 56, and 28, corresponding to the
loss of SO2 and fragmentation of the (CH2)4 chain. The
molecular ion (m/z 120) was abundant enough (28 %) to
be selected as the precursor ion for two MS/MS transitions,
which avoided the selection of very low mass fragments.
This produced better selectivity and a substantial increase in
the sensitivity of the method. In the case of Bu converted to
di-TFTP butane, the molecular ion (m/z 418) was also
abundant enough (34 %) to develop one MS/MS identifica-
tion transition (Fig. 1b). The most abundant fragment (m/z
Fig. 1 Mass spectra of
sulfolane (a) and busulfan
derivatized to 1,4-TFTP-butane
(b) after electron impact
ionization. X-axis represents
mass to charge ratio (m/z), and
y-axis represents relative
abundance in percentage and is
related to the number of times
an ion of a specific m/z ratio
strikes the detector
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237), corresponding to the loss of one TFTP group, was
selected as the precursor ion for a quantitative transition.
Validation
During the pre-validation step, it was determined that a 1/X2
and 1/X weighted linear regression models were the most
suitable for Su and Bu, respectively, giving the most repre-
sentative response function. Validation data are summarized
in Table 2.
Selectivity and carryover
Selectivity was evaluated by injecting five different blank
plasma samples, including the pooled plasma and patients’
plasma prior to infusion of Bu, to check the absence of an
interfering peak at the retention times of interest. Figure 2a, e
shows the typical chromatograms of extracted blank plasma,
demonstrating the absence of interferences for Bu and Su
transitions. Figure 2b, f shows chromatograms for blank plas-
ma spiked with Bu (200 ng/mL) and Su (20 ng/mL). No
Table 2 Validation summary of quantification method for sulfolane
Analyte Concentration of quality
control sample (ng/mL)
Trueness (%)
(k04; n04; p03)
Repeatability (R.S.D. %)
(k04; n04; p03)
Intermediate precision (R.S.D. %)
(k04; n04; p03)
Sulfolane 20 118.0 4.4 11.4
40 100.3 6.8 9.2
100 102.1 7.1 11.7
400 109.3 7.7 11.6
Busulfan 100 113.2 4.9 7.2
200 109.2 5.4 6.7
500 97.6 6.9 9.4
2,000 106.1 10.5 10.5
Regression equations for sulfolane Day 1 Y00.0017X−0.0262 R200.985
Day 2 Y00.0018X−0.0180 R200.989
Day 3 Y00.0017X−0.0265 R200.972
Regression equations for busulfan Day 1 Y00.0009X−0.0647 R200.994
Day 2 Y00.0007X+0.0434 R200.997
Day 3 Y00.0007X+0.0272 R200.980
k is the number of concentration levels, n is the number of repetitions by level, and p is the number of nonconsecutive days. The regression
equations used for calculations of Su after 1/X2 weighting for each of the 3 days generated with calibrator samples run in duplicates at five
concentration levels (20, 50, 100, 200, and 500 ng/mL). Regression equations for Bu were 1/X weighted generated with calibrator samples run in
duplicates at five concentration levels (50, 200, 500, 1,000, and 2,000 ng/mL). The measured concentration values at each quality control
concentration level include mean±SD of values injected in quadruplicates on each of the three validation days. This validation was performed using
the same plasma sample in which both Bu and Su were spiked for quantification by separate chromatography runs. Repeatability represents the
intra-day variability, whereas intermediate precision represents inter-day variability
Fig. 2 Typical current ion
chromatograms with the
sulfolane GC–MS/MS method
(green) and busulfan GC–MS/
MS method (red), showing
injections of extracted blank
plasma (a, e), extracted spiked
blank plasma (b, f), and
isopropanol (c, g). d An
injection of a 10-μg/mL deriv-
atized busulfan solution
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interfering peak was observed in the transitions of Su when
injecting highly concentrated (10 μg/mL) derivatized Bu, as
shown in Fig. 2d. Carryover was also investigated by
injected isopropanol after four injections of the highest
QC. The chromatograms showed no peaks for both analytes
(Fig. 2c, g).
Linearity, trueness, precision, and lower limit
of quantification
Linearity was calculated by fitting the back-calculated con-
centrations of the QCs as a function of the introduced con-
centrations and by applying the linear regression model
Fig. 3 Time vs. plasma concentration profiles of sulfolane and busul-
fan measured in three different individuals. The sulfolane (red squares)
and busulfan (blue circles) levels were measured at 0, 15, 30 min, 1,
4 h after the first dose and 4 h after each dose infusion up to the 15th
dose. Sulfolane levels were detected at 4 h after the first dose infusion,
but were below the quantifiable levels, hence not included in the graph.
X-axis represents time in hours, and y1-axis represents busulfan con-
centration in nanograms per milliliter, y2-axis represents sulfolane
concentration in nanograms per milliliter. Both y1 (left) and y2 (right)
axes were in logarithmic scale
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based on the least-squares method. The regression equa-
tions for used both analytes and the coefficient of deter-
minations (R2) are given in Table 2. The trueness and
precision were determined for each analyte by injecting
independent QC samples at different concentration levels
and by calculation of the difference between measured
and theoretical concentrations.
For Su, the trueness at 20 ng/mL (lowest QC) was found
to be 118.0 % (<±20 %) and in the range of 100.3–109.3 %
for the other QCs (<±15 %; Table 2). For Bu, the trueness
was found to be 113.2 % (<±15 %) at the lowest QC level
and in the range of 97.6–109.2 % for the other levels
(<±10 %). Precision values were assessed by calculating
the relative standard deviations (RSD). The intra-day var-
iability was expressed as repeatability and inter-day vari-
ability was expressed as the intermediate precision. These
values were less than ±15 % (acceptable levels) for all the
concentrations tested (Table 2). The lowest QC concentra-
tion level for Su (20 ng/mL) and Bu (100 ng/mL) has
trueness and precision less than ±20 %, and hence defined
as the LLOQ. These LLOQ values were fully adequate to
quantify both analytes in patients’ plasma receiving high
doses of Bu. All the calibrator samples had trueness and
precision profiles <±15 %. Validation parameters for Bu quan-
tification were in accordance with previously described litera-
ture [15, 19–22]. To our knowledge, no method for
quantitation of Su in patients’ plasma had been published
before, and no comparison could be made.
Stability of sulfolane in plasma samples and extracts
We explored short-term stability at room temperature and
−20 °C. Extracts were found to be stable for more than 12 h
at room temperature (data not shown). This is much longer
than typical analysis sequence duration. Moreover, no sig-
nificant decrease in Su concentration was observed after
90 days at −20 °C (See ESM Fig. 2).
System stability
The analysis of a large number of samples allowed us to
check the stability of the analytical system (ESM Fig. 3).
The variation of area of the IS1 over 79 successive
injections is relatively high (25 % RSD), partly due to
the variation in the volume of organic layer removed from
the extraction tube and to the variation of the final volume
after evaporation of the ethyl acetate fraction, leading to
disparity in concentration factors over the samples. How-
ever, no significant difference (t test) was observed be-
tween the means of the first and the last ten injections,
indicating good robustness of the analytical method.
Hence, this method showed to be suitable for large-scale
clinical studies.
Application to clinical studies
Figure 3 shows the concentration–time profiles of Su and Bu in
three children receiving intravenous Bu (0.8 mg/kg) over a 2-
h period in a conventional 16-dose protocol [14]. The Bu
concentrations presented a typical pattern, with a rapid increase
and decrease of plasmatic concentrations corresponding to the
first dose intravenous infusion. Bu levels were relatively stable
in individuals measured at 4 h (trough level) after each dose
infusion up to the 15th dose. The Su concentrations showed an
interesting profile. A constant increase in plasma concentra-
tions over the doses was observed. Sulfolane was not detectable
until the end of the 4 h following the first dose infusion, but it
was readily quantifiable after the second dose infusion. Using
large volumes of injections might have improved the sensitivity
of the method and allowed for an earlier detection of Su.
However, this was found to be unnecessary for this study as
the concentrations rapidly reached quantifiable levels in all
three patients. Based on these preliminary observations, three
time points were chosen (4 h after dose 1, 4 h after dose 6, and
0 min after dose 9 infusion) to measure the Su levels in a large
number of patients. The levels of Su and Bu from these samples
at 4 h after dose 6 and 0min after dose 9 infusions are presented
in Table 3. Su was detectable at 4 h after dose 1, but its levels
were around the LLOQ (20 ng/mL), and may not have any
analytical or clinical significance, hence were not discussed
here. Higher levels of Su were observed after dose 9 infusion.
All the plasma samples used for analysis were stored for more
than 6 months (up to 3 years) at −80 °C. We also observed
interindividual variability in the levels of both Bu and Su. Thus,
by using this method, one can investigate the role of Su in
determining adverse events and drug interactions during Bu
treatment using plasma samples collected for routine Bu mon-
itoring and during clinical studies.
Conclusion
This novel method presented in this article allowed the
determination of Su in plasma micro samples. Validation
Table 3 Sulfolane and busulfan levels measured in real patient samples
Sample Sulfolane (ng/mL) Busulfan (ng/mL)
Before dose 7 infusion
(n056)
181.9±80.9 (179.1) 393.4±184.8 (365.7)
End of dose 9 infusion
(n054)
249.9±123.4 (239.9) 1262.5±538.5 (1196.3)
All values are mentioned as mean±SD (median). The plasma levels of
Su measured at 4 h after the first dose may not represent exact
quantifiable levels since the lower limit of quantification is 20 ng/
mL, and the values were around 20 ng/mL and are not mentioned
(n046) here due to the lack of analytical and clinical significance, but
Su can be detected 4 h after starting busulfan first dose infusion
A novel method for quantification of sulfolane in plasma GC–MS/MS 1837
data showed a satisfactory degree of sensitivity, trueness,
and precision. The extraction procedure for Su is fast and
simple, and can easily be included in the routine analysis of
Bu as no extra volume of plasma is required. Clinical studies
may adopt this method for investigating the Bu metabolic
fate and its mechanisms of toxicity. The method described
here may be used for understanding the kinetics of Su in
subjects receiving Bu infusion and its role in the adverse
effects and drug interactions seen with Bu therapy.
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